Uveitis

Shares of Clearside Biomedical Inc (NASDAQ: CLSD) has 91 percent upside, according to a note from Stifel, which initiated coverage of the stock with a Buy rating and $13 price target. "Clearside has developed a novel ocular injection platform to deliver drug[s] optimally throughout the eye by way...

In an interview with Benzinga, Aldeyra Therapeutics (NASDAQ: ALDX) CEO Dr. Todd Brady discussed his company’s opportunities. “What we have is an aldehyde trap,” began Brady. “We developed molecules that bind to and dispose of aldehyde.” Aldehydes are an agent in...